STENT DELIVERY SYSTEMS: ENDEAVOR TRIALS

Seven Interventional Cardiologists Review the ENDEAVOR Trials and the Impact of Delivery System

October 10, 2007

Deliverable: Panel transcripts with executive summary.

Objectives:To conduct a panel discussion among interventional cardiologists to examine the data from the ENDEAVOR I, II, and III studies, and explore the potential impact of the Endeavor stent delivery system on the outcomes of the trials as well as the market adoption of the Endeavor Drug Eluting Coronary Stent.  Specifically;

·       Review data from ENDEAVOR I, II, and III and differentiate results by delivery technology

·       Assess perception of the results of the ENDEAVOR studies and the impact of delivery technology on the findings, particularly as they relate to safety

·       Discuss potential conclusions that can be drawn based on the amount and duration of data available

·       Investigate expected impact of approval of Endeavor on current treatment practices 

Companies and Products Mentioned in This Report

Screening Criteria:

·       U.S.-based interventional cardiologists

·       Board-certified

·       Practice in an academic medical center or center of excellence

·       Perform a high volume of drug-eluting stent placements

·       No current consulting arrangements with Cordis, Boston Scientific, Abbott, or Medtronic

Representative Institutions:

·       Deborah Heart Center in Browns Mills

·       Cardiovascular Institute of the South; Terrebonne General Hospital

·       Lutheran General Hospital

·       Columbia University Medical Center / NYPH / Mary Imogene Bassett Hospital

·       Long Island College Hospital

·       Texas Medical Center, Houston

·       Eastern Maine Medical Center